Actively Recruiting
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Led by Sun Yat-sen University · Updated on 2022-07-01
264
Participants Needed
2
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.
CONDITIONS
Official Title
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Performance Status Score 0-1 points.
- Histologically or cytologically confirmed non-keratinized nasopharyngeal carcinoma (WHO type II or III).
- Surgically resectable primary nasopharyngeal tumor classified as T1, T2, or T3 with clinical stage T1-3N1-3M0 or T2-3N0M0 (Stage II-IVA) per AJCC v8.
- Surgically resectable cervical lymph nodes without invasion of major vessels or structures.
- Surgically resectable retropharyngeal lymph nodes with intact capsule or measuring 1.5 cm or less with adequate mouth opening.
- Adequate organ function including specific blood counts and liver, kidney, and coagulation parameters.
- Signed informed consent agreeing to follow-up and study procedures.
You will not qualify if you...
- Recurrent or distant metastatic nasopharyngeal carcinoma or other malignancies.
- Severe heart or lung disease with grade 3 or worse function.
- Extensive tumor invasion beyond resectable areas such as skull base invasion or tumor close to internal carotid artery less than 0.75 cm.
- Retropharyngeal lymph nodes involved or too close to nasopharyngeal tumor (less than 0.75 cm).
- Inability to comply with follow-up due to psychological, social, or geographical reasons.
- Pregnancy or breastfeeding.
- Other conditions deemed unsuitable by the chief physician.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
2
Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
M
Ming-yuan Chen, MD, PhD
CONTACT
R
Rui You, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here